Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Rating of “Hold” from Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received an average recommendation of “Hold” from the twelve research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $76.4167.

A number of research analysts recently commented on the company. Wells Fargo & Company boosted their price target on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Evercore boosted their target price on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Barrington Research set a $79.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HSIC. The Manufacturers Life Insurance Company grew its holdings in shares of Henry Schein by 0.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 75,603 shares of the company’s stock valued at $5,714,000 after purchasing an additional 411 shares during the last quarter. Zuckerman Investment Group LLC boosted its position in Henry Schein by 2.3% in the fourth quarter. Zuckerman Investment Group LLC now owns 287,843 shares of the company’s stock valued at $21,755,000 after buying an additional 6,504 shares in the last quarter. Bridgewater Associates LP grew its stake in shares of Henry Schein by 113.7% during the fourth quarter. Bridgewater Associates LP now owns 7,413 shares of the company’s stock worth $560,000 after buying an additional 3,944 shares during the last quarter. Bank of Nova Scotia increased its holdings in shares of Henry Schein by 19.6% during the fourth quarter. Bank of Nova Scotia now owns 8,569 shares of the company’s stock worth $648,000 after buying an additional 1,405 shares in the last quarter. Finally, Morgan Stanley lifted its stake in shares of Henry Schein by 6.9% in the 4th quarter. Morgan Stanley now owns 1,495,602 shares of the company’s stock valued at $113,038,000 after acquiring an additional 96,730 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 0.3%

NASDAQ HSIC opened at $78.19 on Friday. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The company has a market cap of $9.20 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 2.33 and a beta of 0.88. The company has a 50 day moving average of $77.09 and a 200-day moving average of $71.29. Henry Schein has a 1-year low of $60.56 and a 1-year high of $82.80.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.